{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:54:39Z","timestamp":1789239279728,"version":"build-2803163510"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Children\u2019s Oncology Group study AALL1931 investigated the ef\ufb01cacy and safety of recombinant Erwinia asparaginase (JZP458) in patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma and hypersensitivity reactions\/silent inactivation to Escherichia coli\u2013derived asparaginases. Each pegylated Escherichia coli asparaginase dose remaining in a patient\u2019s treatment plan was replaced by intramuscular (IM) or IV JZP458 (6 doses) administered Monday\/Wednesday\/Friday (MWF). Three IM cohorts (1a [25\u00a0mg\/m2 MWF], n\u00a0=\u00a033; 1b [37.5\u00a0mg\/m2 MWF], n\u00a0=\u00a083; 1c [25\/25\/50\u00a0mg\/m2 MWF], n\u00a0=\u00a051) and 1 IV cohort (25\/25\/50\u00a0mg\/m2 MWF, n\u00a0=\u00a062) were evaluated. The proportion (95% confidence interval [CI]) of patients maintaining nadir serum asparaginase activity (NSAA) levels of \u22650.1 IU\/mL at the last 72 (primary end point) and 48 hours during course 1 was 90% (95% CI, 81-98) and 96% (95%\u00a0CI, 90-100) in IM cohort 1c, respectively, and 40% (95%\u00a0CI, 26-54) and 90% (95%\u00a0CI, 82-98) in the IV cohort. Population pharmacokinetic modeling results were comparable with observed data, predicting the vast majority of patients would maintain therapeutic NSAA levels when JZP458 is administered IM or IV 25\u00a0mg\/m2 every 48 hours, or IM 25\/25\/50\u00a0mg\/m2 MWF, or with mixed IM and IV administration (IV\/IV\/IM 25\/25\/50\u00a0mg\/m2 MWF). Drug discontinuation occurred in 23% and 56% of patients in the IM and IV cohorts, respectively; 13% and 33% because of treatment-related adverse events (mainly allergic reactions and pancreatitis). JZP458 achieves therapeutic NSAA levels via multiple IM and IV dosing schedules based on combined observed and modeled data with a safety profile consistent with other asparaginases. This trial was registered at www.ClinicalTrials.gov as #NCT04145531.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013346","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T17:54:57Z","timestamp":1729878897000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Recombinant\n                    <i>Erwinia<\/i>\n                    asparaginase (JZP458) in ALL\/LBL: complete follow-up of the Children\u2019s Oncology Group AALL1931 study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-9100","authenticated-orcid":false,"given":"Luke","family":"Maese","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of Utah, Huntsman Cancer Institute, Primary Children's Hospital, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-4700","authenticated-orcid":false,"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children\u2019s Hospital, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Rim","family":"Choi","sequence":"additional","affiliation":[{"name":"3Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirali","family":"Agarwal","sequence":"additional","affiliation":[{"name":"3Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Aoki","sequence":"additional","affiliation":[{"name":"3Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liang","sequence":"additional","affiliation":[{"name":"4Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Lin","sequence":"additional","affiliation":[{"name":"3Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Girgis","sequence":"additional","affiliation":[{"name":"4Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Chen","sequence":"additional","affiliation":[{"name":"3Jazz Pharmaceuticals, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Roller","sequence":"additional","affiliation":[{"name":"4Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayalakshmi","family":"Chandrasekaran","sequence":"additional","affiliation":[{"name":"4Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Iannone","sequence":"additional","affiliation":[{"name":"4Jazz Pharmaceuticals, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7275-7650","authenticated-orcid":false,"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"5Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Raetz","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics and Perlmutter Cancer Center, New York University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-6603","authenticated-orcid":false,"given":"Rachel E.","family":"Rau","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children\u2019s Hospital, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"issue":"3","key":"2025011415311984800_bib1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/cts.12947","article-title":"A\u00a0randomized phase I study to evaluate the safety, tolerability, and pharmacokinetics of recombinant Erwinia asparaginase (JZP-458) in healthy adult volunteers","volume":"14","author":"Lin","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"6","key":"2025011415311984800_bib2","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025011415311984800_bib3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase-associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"Hijiya","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025011415311984800_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood.2022016923","article-title":"Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2\/3 AALL1931 study","volume":"141","author":"Maese","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025011415311984800_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2025011415311984800_bib6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2025011415311984800_bib7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"issue":"7","key":"2025011415311984800_bib8","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1080\/10428194.2018.1542146","article-title":"Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4","volume":"60","author":"Schore","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025011415311984800_bib9","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/cpdd.1002","article-title":"Population pharmacokinetic model development and simulation for recombinant Erwinia asparaginase produced in Pseudomonas fluorescens (JZP-458)","volume":"10","author":"Lin","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"2025011415311984800_bib10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/cts.13499","article-title":"Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia","volume":"16","author":"Lin","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"7","key":"2025011415311984800_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"10","key":"2025011415311984800_bib12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/fon-2021-1288","article-title":"Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences","volume":"18","author":"Burke","year":"2022","journal-title":"Future Oncol"},{"issue":"16","key":"2025011415311984800_bib13","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2217\/fon.14.138","article-title":"How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia","volume":"10","author":"Burke","year":"2014","journal-title":"Future Oncol"},{"issue":"17","key":"2025011415311984800_bib14","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025011415311984800_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.htct.2019.07.010","article-title":"Asparaginase: an old drug with new questions","volume":"42","author":"Cecconello","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"issue":"10","key":"2025011415311984800_bib16","doi-asserted-by":"crossref","first-page":"e29169","DOI":"10.1002\/pbc.29169","article-title":"Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?","volume":"68","author":"Maese","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2025011415311984800_bib17","volume-title":"RYLAZE\u00ae (asparaginase Erwinia chrysanthemi (recombinant)-rywn). Package insert","year":"2024"},{"key":"2025011415311984800_bib18","author":"US Food and Drug Administration","year":"2021"},{"key":"2025011415311984800_bib19","unstructured":"Jazz Pharmaceuticals Ireland Ltd\n          . Enrylaze 10 mg\/0.5 mL solution for injection\/infusion. Summary of product characteristics. 2023. Accessed 5 December 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enrylaze-epar-product-information_en.pdf."},{"key":"2025011415311984800_bib20","author":"Jazz Pharmaceuticals","year":"2022"},{"key":"2025011415311984800_bib21","author":"Jazz Pharmaceuticals","year":"2023"},{"key":"2025011415311984800_bib22","author":"US Food and Drug Administration","year":"2019"},{"key":"2025011415311984800_bib23","author":"Jazz Pharmaceuticals","year":"2020"},{"issue":"3","key":"2025011415311984800_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/10428194.2016.1213826","article-title":"Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia","volume":"58","author":"Burke","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025011415311984800_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.25757","article-title":"Activity and toxicity of intravenous Erwinia asparaginase following Allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia","volume":"63","author":"Vrooman","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025011415311984800_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2013-01-480822","article-title":"Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group","volume":"122","author":"Salzer","year":"2013","journal-title":"Blood"},{"key":"2025011415311984800_bib27","author":"Jazz Pharmaceuticals","year":"2021"},{"key":"2025011415311984800_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/BLCTT.S342052","article-title":"Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and place in therapy","volume":"12","author":"Juluri","year":"2022","journal-title":"Blood Lymphat Cancer"},{"issue":"13","key":"2025011415311984800_bib29","first-page":"987","article-title":"How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia","volume":"135","author":"Aldoss","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025011415311984800_bib30","first-page":"481","article-title":"IV administration of Erwinia-derived asparaginase in pediatric patients with acute lymphoblastic leukemia: single-centre case series","volume":"68","author":"Reniers","year":"2015","journal-title":"Can J Hosp Pharm"},{"issue":"7","key":"2025011415311984800_bib31","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/pbc.24938","article-title":"Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial","volume":"61","author":"Plourde","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2025011415311984800_bib32","author":"Okusanya","year":"28 -1  2015"},{"issue":"2","key":"2025011415311984800_bib33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E.\u00a0coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"2025011415311984800_bib34","author":"Aoki","year":"31 \u20134  2024"},{"issue":"2","key":"2025011415311984800_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2025011415311984800_bib36","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12407","article-title":"Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"162","author":"Samarasinghe","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2025011415311984800_bib37","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2025011415311984800_bib38","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A\u00a0randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2025011415311984800_bib39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol"},{"issue":"13","key":"2025011415311984800_bib40","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A\u00a0prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025011415311984800_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO;2-M","article-title":"Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase","volume":"70","author":"Billett","year":"1992","journal-title":"Cancer"},{"issue":"4","key":"2025011415311984800_bib42","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1365-2141.2001.03009.x","article-title":"Pharmacokinetics of native Escherichia coli asparaginase (asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment","volume":"114","author":"M\u00fcller","year":"2001","journal-title":"Br J Haematol"},{"issue":"5","key":"2025011415311984800_bib43","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2025011415311984800_bib44","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/sj.leu.2401162","article-title":"Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia","volume":"12","author":"Woo","year":"1998","journal-title":"Leukemia"},{"issue":"5","key":"2025011415311984800_bib45","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/10428190701292049","article-title":"The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia","volume":"48","author":"Zalewska-Szewczyk","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2025011415311984800_bib46","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/leu.2012.102","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia","volume":"26","author":"Liu","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2025011415311984800_bib47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/66\/2349807\/blooda_adv-2024-013346-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/66\/2349807\/blooda_adv-2024-013346-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T10:55:26Z","timestamp":1736852126000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/66\/525802\/Recombinant-Erwinia-asparaginase-JZP458-in-ALL-LBL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013346","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}